PD
ATOS icon

Point72 (DIFC)’s Atossa Therapeutics ATOS Stock Holding History

Point72 (DIFC)’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$71 Sell
5
-552
-99% -$6.82K ﹤0.01% 1113
2025
Q2 		$6.94K Buy
+557
New +$6.66K ﹤0.01% 1351

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 (DIFC)'s ATOS Position: Q3 2025 in Review

Point72 (DIFC) reduced its Atossa Therapeutics (ATOS) stake by 99% in Q3 2025, selling an estimated $6.82K and leaving 5 shares worth $71. The position accounts for ﹤0.01% of the portfolio, ranked #1113.

Point72 (DIFC) first reported a position in ATOS in Q2 2025 and has held it in 2 quarters since. The position peaked at $6.94K in Q2 2025. 66 funds tracked by Wall St. Rank hold ATOS as of Q3 2025.

  • Point72 (DIFC) held 5 shares of Atossa Therapeutics worth $71 as of Q3 2025.
  • Point72 (DIFC) sold 552 Atossa Therapeutics shares in Q3 2025, an estimated $6.82K.
  • Atossa Therapeutics made up ﹤0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #1113 holding.
  • Point72 (DIFC) first reported a position in Atossa Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Point72 (DIFC)'s Atossa Therapeutics position peaked at $6.94K in Q2 2025.
  • 66 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.